ABOUT LUTETIA
Building a global biotech for multimodal neurology.
Lutetia Therapeutics was created in 2026 around a clinically advanced CMT1A program and a clear ambition: advance LUT001 while building the next generation of multimodal therapies in CMT1A, ALS and Alzheimer’s disease.
Established in 2026 · Incorporated in Delaware, United States

OUR STARTING POINT
A new company. A tangible starting point.
Lutetia was established in 2026 with something unusual for a new biotechnology company: a clinically advanced starting program and years of accumulated development data.
The 2026 acquisition of Pharnext-origin patents and clinical and regulatory data provides the foundation for LUT001, Lutetia’s lead program in CMT1A.
That foundation allows Lutetia to focus immediately on the questions that matter for the program’s next stage: clinical evidence, CMC and manufacturing, regulatory strategy and execution.
2026
Lutetia Therapeutics established
2026
Pharnext-origin patents and data acquired
Today
LUT001 development strategy and next-generation neurology programs
LEADERSHIP
Leadership for the next stage.
Lutetia brings together leadership across company building, clinical development, data and international biopharma execution.
Board
Jean-Jacques Bienaimé
Executive Chairman
Jean‑Jacques Bienaimé, MBA, is Executive Chairman of Lutetia Therapeutics, overseeing corporate strategy, financing, governance, and commercialization planning. He brings more than three decades of biopharmaceutical leadership, with deep expertise in rare‑disease development and global product launches. For 18 years, he served as Chairman and CEO of BioMarin Pharmaceutical, helping build it into a leading rare‑disease company. Over his career, he contributed to the development and commercialization of eight pediatric rare‑disease therapies. He also serves on multiple biotechnology boards and advises emerging companies on strategic growth and long‑term value creation.

Darith Phat
Founder & Chief Executive Officer
Darith Phat, PhD, MS, MBA, is the Founder and CEO of Lutetia Therapeutics, leading the intellectual‑property acquisition and regulatory rescue of LUT001 (PXT3003) for Charcot‑Marie‑Tooth disease type 1A. A biopharma leader with over a decade of experience in translational research, asset acquisition, and cross‑border partnering, Dr. Phat has advised senior biotech executives and held academic appointments at Georgetown University and École Centrale Paris, mentoring students who later became CEOs of major pharmaceutical companies. He earned his PhD from CentraleSupélec, an MS from UC San Diego, and an MBA from IMD Lausanne, and serves on the board of CamEd Business School.

Executive leadership
Key Operations / Functional Leads
Jamunabai Prakash, MS (Jem):
VDR & IP Management / Alliance Management / Operations

Yannis Jemiai
Fractional Chief Data Science Officer
Yannis Jemiai, PhD, is Co-Founder and Chief Data Science Officer at Lutetia Therapeutics, leading statistical strategy for its neuroscience pipeline. With over 20 years of experience in biostatistics and clinical development, he applies adaptive and Bayesian trial design, causal inference, real-world evidence and AI/ML. Former Chief Scientific Officer at Cytel, he guided its consulting and software divisions through two private-equity transactions. He holds a Harvard PhD in Biostatistics and advises multiple life-science companies.

Priya Jambhekar
Chief Regulatory and Quality Officer & Scientific Advisory Board Member
Priya Jambhekar is Chief Regulatory & Quality Officer at Lutetia Therapeutics, leading LUT001’s global regulatory strategy, health authority interactions and quality systems. With over 30 years of experience, she is President and CEO of PBS Regulatory Consulting Group. Previously, she served as Global SVP of Regulatory & Quality at Paramount BioSciences and Global VP at Ethicon (Johnson & Johnson) and Alkermes. She has guided numerous global NDA, MAA and IND filings for small molecules, biologics and cell therapies through the FDA, EMA and other health authorities.

Praveen Kandi
Vice President, Head of CMC
Praveen Kandi, PhD, is CMC Head at Lutetia Therapeutics, bringing over 22 years of experience in CMC strategy, drug development, technology transfer and commercialization. His career spans Amani Therapeutics, RTW Investments, Transneural Therapeutics, Bristol Myers Squibb–Karuna Therapeutics and Thermo Fisher Scientific. A key CMC leader for COBENFY® (KarXT), he contributed to its FDA approval. He combines scientific expertise, operational excellence and strategic partnership leadership to accelerate development, optimize capital efficiency and advance innovative medicines toward global commercialization.
Carlos Gonzalez
Fractional Chief Financial Officer
Carlos Gonzalez is CFO at Lutetia Therapeutics, overseeing financial planning, reporting and Series A diligence readiness. He brings over 30 years of experience, including 20+ fractional CFO engagements with VC-backed startups from Seed to Series A, notably in biotech. Previously, he served as CFO of a €1.8 billion investment fund. An IESE Executive MBA graduate, he has worked across the US, Europe and Singapore and is active in the San Francisco Bay Area startup ecosystem, with a particular interest in AI and finance.

SCIENTIFIC & STRATEGIC ADVISORS
Scientific & Strategic Advisory Boards
I — Lutetia Scientific Advisory Board (SAB), Opinion Leaders (KOLs)
CMT & Neurology Clinical Experts
Additional Scientific & Regulatory Expertise
II — Strategic Advisory Board & Commercial Leaders
Commercial & Valuation Strategy
Lauren Cohen, PhD
Member, Commercial & Valuation Strategy (L.E. Simmons Chaired Professor, Harvard Business School).
Dr. David Herrmann
Professor of Neurology & Neuromuscular Division Chief (University of Rochester); leading collaboration on ACT-CMT natural history datasets and longitudinal ONLS/CMTNS endpoint controls.
Dr. Florian Thomas
Chair of Neurology & Director, CMT Center of Excellence (Hackensack Meridian); advising on neuromuscular clinical trials, natural history trajectories, and patient registry integration.
Dr. Michael Sereda
Professor of Neurology & Head of Neurogenetics (University Medical Center Göttingen / Max Planck Institute); engaged regarding German NHS dataset analysis, meta-analysis steering committee, and CMT endpoint evaluation.
Clinical & Regulatory Strategy
Jonathon Parker, PhD
Lead Regulatory Advisor (SAB); packaging FDA regulatory narrative, aligning US/China trial data, and guiding Pre-NDA strategy.
Biostatistics & Regulatory Strategy
Philippe Lehert, PhD
Lead Biostatistician (SAB); former UN Senior Consulting Statistician directing meta-analyses, pooled trial re-evaluations, and statistical strategies.
Regulatory & CMC Strategy
Ramesh Sood, PhD
Member, Scientific Advisory Board (Former FDA CMC Branch Chief & Regulatory Strategy Advisor).
Formulation & Drug Delivery
Rodney JY Ho, PhD
Member, CMC Advisory Board (Professor of Pharmaceutics, University of Washington); specialist in combination drug solutions, formulation stability, and delivery platforms.

PURPOSE
A clear purpose. A bold but focused ambition.
MISSION
Advance therapies with the potential to make a meaningful difference for people living with serious neurological diseases.
VISION
Address biological complexity through rigorous multimodal therapeutic strategies.
AMBITION
Build a globally relevant neurology biotech anchored by LUT001 and expanded through next-generation CMT1A, ALS and Alzheimer’s disease programs.

HOW WE BUILD
Advance. Create. Execute.
Scientific potential creates opportunity. Development discipline turns that opportunity into progress.
Advance
Move LUT001 toward the most rigorous feasible global development path.
Create
Build next-generation multimodal programs with scientific discovery collaborators.
Execute
Bring together the clinical, regulatory, data, CMC, manufacturing and partnering capabilities needed to move selected programs forward.
Different programs require different capabilities. Lutetia’s model is designed to assemble the expertise each stage demands.
GLOBAL BY DESIGN
Global from the start.
Lutetia is building its development strategy across the United States and Europe, with Japan under evaluation. The company’s scientific and development network is intentionally international.
For LUT001, clinical evidence, manufacturing requirements and regulatory feedback will determine the path forward. Future programs will be built with the same global development mindset.
United States
Development and regulatory strategy
Europe
Clinical and regulatory planning
Japan
Opportunity under evaluation
The separate PXT3003 program in China is led by Tasly/GeneNet.

WHAT COMES NEXT
Building the next generation of multimodal therapies in neurology.
Lutetia is combining a clinically advanced starting program with a focused research pipeline and a global development mindset.
We welcome conversations with investors, biopharma partners and scientific collaborators who want to help turn that potential into progress.
